Chino Hills, CA, Aug. 09, 2018 (GLOBE NEWSWIRE) -- We are advised by SOHM, Inc. (PINKSHEETS: SHMN) that journalists and other readers should disregard the news release, "SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug," issued Thursday, August 9, 2018, over GlobeNewswire.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.001 USD | -9.09% | -16.67% | -28.57% |
1st Jan change | Capi. | |
---|---|---|
-28.57% | 0 | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- SHMN Stock
- News SOHM INC
- NOTICE TO DISREGARD - SOHM, Inc.